將46例進展期胃癌患者在行根治性切除術(shù)后隨機分為實驗組(n＝25)和對照組(n＝21)，兩組患者的年齡、性別、癌腫侵及胃壁的深度及組織學(xué)類型等相似，且具有可比性。實驗組在術(shù)畢立即用43℃熱低滲液(重蒸餾水)2500～3000ml腹腔內(nèi)灌注，30分鐘后留灌注液700～1000ml于腹腔內(nèi)，并于注入順鉑(60～200mg/m2)的同時，靜脈輸入其解毒劑硫代硫酸鈉(7.5g/m2)。結(jié)果：實驗組灌注前9例癌細(xì)胞陽性者，灌注后均轉(zhuǎn)為陰性；與對照組相比，1年生存率前者為96%，后者為48.54%，差異有顯著性(Ｐ＜0.01)，但1年半生存率差異則無統(tǒng)計學(xué)意義(Ｐ＞0.05)。該法具有胃腸道反應(yīng)輕微，無嚴(yán)重腎、骨髓毒性反應(yīng)和肝及周圍神經(jīng)損害，也無嚴(yán)重并發(fā)癥等優(yōu)點，值得進一步擴大例數(shù)，作更遠期的療效觀察。
引用本文： 陳志新,彭德恕,鄭吉祥. 大劑量順鉑“雙路化療”在胃癌術(shù)中的臨床應(yīng)用研究. 中國普外基礎(chǔ)與臨床雜志, 1995, 2(2): 84-86. doi: 復(fù)制
版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
| 1. | Fujimoto S, Shretha RD, Kokubun M. Intraoperationeal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg, 1988;208:36. |
| 2. | Howell SB, Pfeifle CE, Wang WE. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res, 1983;43:1426. |
| 3. | 徐淑云.臨床用藥指南.合肥：安徽科學(xué)技術(shù)出版社，1989：8. |
| 4. | Howell SB, Richard A, Craig E. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med, 1982;97:805. |
| 5. | Howell SB, Kirmanis S, Licas WE. A phase trial of intraperitoneal cisplatin and etoposide for primary ovaran epithelial cancer. J Clin Oncol, 1990;8:137. |
| 6. | Mcvie TG. Tissue concetration of platinum after intraperitoneal cisplatinum administration in patients. Proc Am Assoc Cancer Res, 1985;26:162. |
| 7. | Spyper TL. The rationale behind intraperitoneal chemotherapy in gastraintestinal malignancies. Semin col, 1985;13:23. |
| 8. | Los G, Smals OA, Van Vugt MJ. A rationale behind intraperitoneal for carcoplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity cancer Res, 1992;52:1252. |
| 9. | Kui Chi S, Fujimoto S, Dkui K. Experimental study of heatinduced total cellular killing of human gastric cancer cells with particular reference to the thermal dose required to achieve total cellular killing. Jpn J Cancer Clin, 1991;37(5):500. |
| 10. | 陳俊青.低滲液、溫?zé)釋w外培養(yǎng)胃癌細(xì)胞系MGC-803殺傷效應(yīng)的實驗研究.中國醫(yī)科大學(xué)學(xué)報，1990；19(4)：269. |
- 1. Fujimoto S, Shretha RD, Kokubun M. Intraoperationeal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg, 1988;208:36.
- 2. Howell SB, Pfeifle CE, Wang WE. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res, 1983;43:1426.
- 3. 徐淑云.臨床用藥指南.合肥：安徽科學(xué)技術(shù)出版社，1989：8.
- 4. Howell SB, Richard A, Craig E. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med, 1982;97:805.
- 5. Howell SB, Kirmanis S, Licas WE. A phase trial of intraperitoneal cisplatin and etoposide for primary ovaran epithelial cancer. J Clin Oncol, 1990;8:137.
- 6. Mcvie TG. Tissue concetration of platinum after intraperitoneal cisplatinum administration in patients. Proc Am Assoc Cancer Res, 1985;26:162.
- 7. Spyper TL. The rationale behind intraperitoneal chemotherapy in gastraintestinal malignancies. Semin col, 1985;13:23.
- 8. Los G, Smals OA, Van Vugt MJ. A rationale behind intraperitoneal for carcoplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity cancer Res, 1992;52:1252.
- 9. Kui Chi S, Fujimoto S, Dkui K. Experimental study of heatinduced total cellular killing of human gastric cancer cells with particular reference to the thermal dose required to achieve total cellular killing. Jpn J Cancer Clin, 1991;37(5):500.
- 10. 陳俊青.低滲液、溫?zé)釋w外培養(yǎng)胃癌細(xì)胞系MGC-803殺傷效應(yīng)的實驗研究.中國醫(yī)科大學(xué)學(xué)報，1990；19(4)：269.